Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955939 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03955939: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT03955939 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03955939, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
Primary Outcome
Number of Participants with Dose Reductions
Interventions
- DRUG Midazolam
- DRUG Endocrine therapy
- DRUG LY3295668 Erbumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2020-05-14 |
| Phase | Phase 1 |
What the finished NCT03955939 record still lists
NCT03955939 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT03955939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03955939 about?
NCT03955939 is a clinical study titled "A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body". The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
What is the current status of trial NCT03955939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-08-02. Estimated completion is 2020-05-14.
What interventions are being tested in trial NCT03955939?
The interventions under investigation include: Midazolam (DRUG), Endocrine therapy (DRUG), LY3295668 Erbumine (DRUG).
Who is sponsoring clinical trial NCT03955939?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03955939's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI